{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:14:03Z","timestamp":1776352443542,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Womens Ment Health"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Opioid agonist treatment (OAT) is the first-line treatment for opioid dependence during pregnancy and recommended for at least one year postpartum or until a strong maternal-infant bond and stable family environment is established. Evidence on postpartum OAT retention is limited. We examined retention rates and associated maternal characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We linked OAT prescription authority to perinatal, mortality, and other data sources. We identified all opioid-dependent women who gave birth in New South Wales, Australia (1 January 2004-31 March 2020) while receiving OAT. We defined retention at 90, 180, and 365 days postpartum as continuous treatment over each period. We calculated retention rates and used generalised linear modelling to examine association between retention and maternal socio-demographic and clinical factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 3933 childbirths among 2514 women on OAT. Retention rates were 93.3% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093670) at 90 days, 88.4% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093475) at 180 days, and 78.5% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093086) at 365 days. Retention at 180 days was lower for those who gave birth after 2015, were Indigenous, had recent conviction or incarceration, initiated OAT after conception, received buprenorphine, or had a mental illness. We observed similar association patterns at 90 and 365 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among women on OAT at childbirth, postpartum treatment retention was high but varied across subgroups. Lower retention among women who initiated OAT late in pregnancy or with social or clinical risk factors highlights the need for targeted support. Lower buprenorphine retention warrants ongoing monitoring and tailored care, particularly in settings where it is the preferred treatment during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00737-025-01640-8","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:27:30Z","timestamp":1767666450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Postpartum retention in opioid agonist treatment for opioid dependence: A population-based cohort study"],"prefix":"10.1007","volume":"29","author":[{"given":"Joanna","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Varney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chrianna","family":"Bharat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alys","family":"Havard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duong Thuy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1640_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.109868","volume":"247","author":"AE Austin","year":"2023","unstructured":"Austin AE, Durrance CP, Ahrens KA, Chen Q, Hammerslag L, McDuffie MJ, Talbert J, Lanier P, Donohue JM, Jarlenski M (2023) Duration of medication for opioid use disorder during pregnancy and postpartum by race\/ethnicity: results from 6 state Medicaid programs. Drug Alcohol Depend 247:109868","journal-title":"Drug Alcohol Depend"},{"key":"1640_CR2","unstructured":"Australian Bureau of Statistics (2022) Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia [Online]. Available: https:\/\/www.abs.gov.au\/websitedbs\/censushome.nsf\/home\/seifa2011 [Accessed: 01\/07\/2025]"},{"key":"1640_CR3","unstructured":"Australian Bureau of Statistics (2024) Births, Australia [Online]. ABS. Available: https:\/\/www.abs.gov.au\/statistics\/people\/population\/births-australia\/2024 [Accessed: 01\/07\/2025]"},{"key":"1640_CR4","unstructured":"Australian Centre for Housing Research (2023) Accessibility\/Remoteness Index of Australia (ARIA +). [Online]. Available: https:\/\/able.adelaide.edu.au\/housing-research\/data-gateway\/aria [Accessed: 01\/07\/2025]"},{"key":"1640_CR5","unstructured":"Australian Injecting and Illicit Drug Users League (2025) About AIVL [Online]. Available: https:\/\/aivl.org.au\/about-aivl\/"},{"key":"1640_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104255","volume":"123","author":"C Bharat","year":"2024","unstructured":"Bharat C, Chidwick K, Gisev N, Farrell M, Ali R, Degenhardt L (2024) Trends in use of medicines for opioid agonist treatment in Australia, 2013\u20132022. Int J Drug Policy 123:104255","journal-title":"Int J Drug Policy"},{"key":"1640_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/add.12834","volume":"110","author":"L Burns","year":"2015","unstructured":"Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J, Larance B, Mattick RP, Butler T, Degenhardt L (2015) A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in new South Wales, Australia. Addiction 110:646\u2013655","journal-title":"Addiction"},{"key":"1640_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1360-0443.2006.01651.x","volume":"102","author":"L Burns","year":"2007","unstructured":"Burns L, Mattick RP, Lim K, Wallace C (2007) Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction 102:264\u2013270","journal-title":"Addiction"},{"key":"1640_CR9","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","volume":"11","author":"S Colledge-Frisby","year":"2023","unstructured":"Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB, Hajarizadeh B, Leung J, Peacock A, Vickerman P, Farrell M, Dore GJ, Hickman M, Degenhardt L (2023) Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Glob Health 11:e673\u2013e683","journal-title":"Lancet Glob Health"},{"key":"1640_CR10","volume-title":"Review of Australian initiatives to reduce stigma experienced by people who use alcohol and other drugs when accessing health services","author":"A Conway","year":"2022","unstructured":"Conway A, Treloar BL C (2022) Review of Australian initiatives to reduce stigma experienced by people who use alcohol and other drugs when accessing health services. UNSW Centre for Social Research in Health, Sydney"},{"key":"1640_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108420","volume":"131","author":"H Coupland","year":"2021","unstructured":"Coupland H, Moensted ML, Reid S, White B, Eastwood J, Haber P, Day C (2021) Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: service provider perspectives. J Subst Abuse Treat 131:108420","journal-title":"J Subst Abuse Treat"},{"key":"1640_CR12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","volume":"10","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Clark B, Macpherson G, Leppan O, Nielsen S, Zahra E, Larance B, Kimber J, Martino-Burke D, Hickman M, Farrell M (2023) Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. Lancet Psychiatry 10:386\u2013402","journal-title":"Lancet Psychiatry"},{"key":"1640_CR13","doi-asserted-by":"publisher","first-page":"B5","DOI":"10.1016\/j.ajog.2019.03.022","volume":"221","author":"J Ecker","year":"2019","unstructured":"Ecker J, Abuhamad A, Hill W, Bailit J, Bateman BT, Berghella V, Blake-Lamb T, Guille C, Landau R, Minkoff H, Prabhu M, Rosenthal E, Terplan M, Wright TE, Yonkers KA (2019) Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the society for Maternal-Fetal medicine, American college of obstetricians and Gynecologists, and American society of addiction medicine. Am J Obstet Gynecol 221:B5\u2013b28","journal-title":"Am J Obstet Gynecol"},{"key":"1640_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/ADM.0000000000000467","volume":"13","author":"JD Ellis","year":"2019","unstructured":"Ellis JD, Cairncross M, Struble CA, Carr MM, Ledgerwood DM, Lundahl LH (2019) Correlates of treatment retention and opioid misuse among postpartum women in methadone treatment. J Addict Med 13:153\u2013158","journal-title":"J Addict Med"},{"key":"1640_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.anzjph.2024.100127","volume":"48","author":"AM Grech","year":"2024","unstructured":"Grech AM, Sharma S, Kizirian N, Gordon A (2024) Impact of the COVID-19 pandemic on new parents enrolled in the \u2018BABY1000\u2019 birth cohort study in Sydney, Australia: a mixed-methods study. Aust N Z J Public Health 48:100127","journal-title":"Aust N Z J Public Health"},{"key":"1640_CR16","doi-asserted-by":"publisher","first-page":"104939","DOI":"10.1016\/j.healthpol.2023.104939","volume":"138","author":"NY Hall","year":"2023","unstructured":"Hall NY, Le L, Abimanyi-Ochom J, Mihalopoulos C (2023) Measuring the importance of different barriers to opioid agonist treatment using best-worst scaling in an Australian setting. Health Policy 138:104939","journal-title":"Health Policy"},{"key":"1640_CR17","unstructured":"Huber PJ (1967) The Behavior of Maximum Likelihood Estimates under Nonstandard Conditions In: Proceedings of the 5th Berkeley Symposium on Mathematical Statistics and Probability, University of California Press,. Proceedings of the 5th Berkeley Symposium on Mathematical Statistics and Probability"},{"key":"1640_CR18","unstructured":"Institute for Health Metrics and Evaluation (2025) Global Burden of Disease: Compare [Online] [Online]. Available: https:\/\/www.thelancet.com\/lancet\/visualisations\/gbd-compare [Accessed: 01\/07\/2025]"},{"key":"1640_CR19","doi-asserted-by":"crossref","unstructured":"Jones N, Ghouse FN, Gibson A, Tran DT, Santo T Jr, Bharat C, Farrell M, Degenhardt L (2025) Data resource profile update: the opioid agonist treatment and safety II (OATS II) Study, 2001\u201322, new South Wales, Australia. Int J Epidemiol, 54","DOI":"10.1093\/ije\/dyaf037"},{"key":"1640_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108464","volume":"219","author":"NR Jones","year":"2021","unstructured":"Jones NR, Nielsen S, Farrell M, Ali R, Gill A, Larney S, Degenhardt L (2021) Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001\u20132018: implications for treatment systems and potential impact on client outcomes. Drug Alcohol Depend 219:108464","journal-title":"Drug Alcohol Depend"},{"key":"1640_CR21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1080\/10826084.2022.2083174","volume":"57","author":"M Kinsella","year":"2022","unstructured":"Kinsella M, Halliday LOE, Shaw M, Capel Y, Nelson SM, Kearns RJ (2022) Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis. Subst Use Misuse 57:1400\u20131416","journal-title":"Subst Use Misuse"},{"key":"1640_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/08897077.2016.1146649","volume":"37","author":"EE Krans","year":"2016","unstructured":"Krans EE, Bogen D, Richardson G, Park SY, Dunn SL, Day N (2016) Factors associated with buprenorphine versus methadone use in pregnancy. Subst Abus 37:550\u2013557","journal-title":"Subst Abus"},{"key":"1640_CR23","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1111\/add.15582","volume":"116","author":"EE Krans","year":"2021","unstructured":"Krans EE, Kim JY, Chen Q, Rothenberger SD, James AE 3rd, Kelley D, Jarlenski MP (2021) Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction 116:3504\u20133514","journal-title":"Addiction"},{"key":"1640_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s12889-017-4785-7","volume":"17","author":"S Larney","year":"2017","unstructured":"Larney S, Hickman M, Guy R, Grebely J, Dore GJ, Gray RT, Day CA, Kimber J, Degenhardt L (2017) Estimating the number of people who inject drugs in Australia. BMC Public Health 17:757","journal-title":"BMC Public Health"},{"key":"1640_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/pds.4647","volume":"28","author":"WH Lo-Ciganic","year":"2019","unstructured":"Lo-Ciganic WH, Donohue JM, Kim JY, Krans EE, Jones BL, Kelley D, James AE, Jarlenski MP (2019) Adherence trajectories of buprenorphine therapy among pregnant women in a large state medicaid program in the united States. Pharmacoepidemiol Drug Saf 28:80\u201389","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1640_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2023.101173","volume":"5","author":"CE Martin","year":"2023","unstructured":"Martin CE, Britton E, Shadowen H, Johnson J, Sabo R, Cunningham P (2023) Postpartum medication for opioid use disorder outcomes associated with prenatal treatment and neighborhood-level social determinants. American Journal of Obstetrics & Gynecology MFM 5:101173","journal-title":"American Journal of Obstetrics & Gynecology MFM"},{"key":"1640_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112454","volume":"264","author":"M Mburu","year":"2024","unstructured":"Mburu M, Masese R, Knippler ET, Watt MH, Muhirwa A, Ledbetter L, Graton M, Knettel BA (2024) Factors associated with medications for opioid use disorder (MOUD) treatment success during the pregnancy and postpartum periods: a scoping review. Drug Alcohol Depend 264:112454","journal-title":"Drug Alcohol Depend"},{"key":"1640_CR28","doi-asserted-by":"crossref","unstructured":"Nawaz N, Hester M, Oji-Mmuo CN, Gomez E, Allen AM (2022) Risk Factors Associated with Perinatal Relapse to Opioid Use Disorder. Neoreviews, 23, e291-e299. Network of Alcohol and Other Drugs Agencies 2025. About","DOI":"10.1542\/neo.23-5-e291"},{"key":"1640_CR29","unstructured":"New South Wales Ministry of Health (2018) NSW Clinical Guidelines: Treatment of Opioid Dependence 2018 [Online]. Available: https:\/\/www.health.nsw.gov.au\/aod\/Publications\/nsw-clinical-guidelines-opioid.pdf [Accessed: 03\/07\/2025]"},{"key":"1640_CR30","unstructured":"New South Wales Ministry of Health 2024 Clinical guidance for the management of substance use in Pregnancy, birth and the postnatal period [Online]. NSW"},{"key":"1640_CR31","unstructured":"Nicholas R (2022) Opioid Agonist Therapy in Australia: A History. [Online]. Adelaide: National Centre for Education and Training on Addiction (NCETA). Available: https:\/\/nceta.flinders.edu.au\/application\/files\/6316\/5456\/3757\/Final_version_OAT_History_Report.pdf [Accessed: 05\/07\/2025]"},{"key":"1640_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2017.12.001","volume":"86","author":"AB O\u2019Connor","year":"2018","unstructured":"O\u2019Connor AB, Uhler B, O\u2019Brien LM, Knuppel K (2018) Predictors of treatment retention in postpartum women prescribed buprenorphine during pregnancy. J Subst Abuse Treat 86:26\u201329","journal-title":"J Subst Abuse Treat"},{"key":"1640_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jsat.2014.04.004","volume":"47","author":"CA Pace","year":"2014","unstructured":"Pace CA, Kaminetzky LB, Winter M, Cheng DM, Saia K, Samet JH, Walley AY (2014) Postpartum changes in methadone maintenance dose. J Subst Abuse Treat 47:229\u2013232","journal-title":"J Subst Abuse Treat"},{"key":"1640_CR34","unstructured":"Pharmaceutical Benefits Scheme (2025) Opioid Dependence Treatment Program [Online]. Available: https:\/\/www.pbs.gov.au\/browse\/section100-md [Accessed: 21\/10\/2025]"},{"key":"1640_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ajad.13084","volume":"30","author":"S Ray-Griffith","year":"2021","unstructured":"Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, Stowe ZN (2021) Buprenorphine medication for opioid use disorder: a study of factors associated with postpartum treatment retention. Am J Addict 30:43\u201348","journal-title":"Am J Addict"},{"key":"1640_CR36","unstructured":"Royal Hospital for Women (2024) Substance Use in Pregnancy and Parenting Service (SUPPS) [Online]. South Eastern Sydney Local Health District NSW Health. Available: https:\/\/www.seslhd.health.nsw.gov.au\/royal-hospital-for-women\/services-clinics\/directory\/pregnancy\/substance-use-pregnancy-and-parenting-service-supps [Accessed: 01\/07\/2025]"},{"key":"1640_CR37","unstructured":"SAS Institute Inc (2011) SAS\u00ae 9.3 Software [Online]. Available: https:\/\/support.sas.com\/software\/93\/ [Accessed: 24\/10\/2025]"},{"key":"1640_CR38","doi-asserted-by":"publisher","first-page":"424.e1","DOI":"10.1016\/j.ajog.2021.04.210","volume":"225","author":"DM Schiff","year":"2021","unstructured":"Schiff DM, Nielsen TC, Hoeppner BB, Terplan M, Hadland SE, Bernson D, Greenfield SF, Bernstein J, Bharel M, Reddy J, Taveras EM, Kelly JF, Wilens TE (2021) Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. Am J Obstet Gynecol 225:424.e1\u2013424.e12","journal-title":"Am J Obstet Gynecol"},{"key":"1640_CR39","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/AOG.0000000000002734","volume":"132","author":"DM Schiff","year":"2018","unstructured":"Schiff DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, Bharel M, Wilens TE, LaRochelle M, Walley AY, Land T (2018) Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol 132:466\u2013474","journal-title":"Obstet Gynecol"},{"key":"1640_CR40","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1056\/NEJMoa2203318","volume":"387","author":"EA Suarez","year":"2022","unstructured":"Suarez EA, Huybrechts KF, Straub L, Hern\u00e1ndez-D\u00edaz S, Jones HE, Connery HS, Davis JM, Gray KJ, Lester B, Terplan M, Mogun H, Bateman BT (2022) Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med 387:2033\u20132044","journal-title":"N Engl J Med"},{"key":"1640_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.wombi.2021.08.010","volume":"35","author":"L Sweet","year":"2022","unstructured":"Sweet L, Wilson AN, Bradfield Z, Hauck Y, Kuliukas L, Homer CSE, Szabo RA, Wynter K, Vasilevski V (2022) Childbearing women\u2019s experiences of the maternity care system in Australia during the first wave of the COVID-19 pandemic. Women Birth 35:223\u2013231","journal-title":"Women Birth"},{"key":"1640_CR42","unstructured":"The American College of Obstetricians and Gynaecologists (2017) Opioid use and opioid use disorder in pregnancy [Online]. American College of Obstetricians and Gynecologists. Available: https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2017\/08\/opioid-use-and-opioid-use-disorder-in-pregnancy [AccessedL 13\/08\/2025]"},{"key":"1640_CR43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11920-019-1110-4","volume":"21","author":"AL Tobon","year":"2019","unstructured":"Tobon AL, Habecker E, Forray A (2019) Opioid use in pregnancy. Curr Psychiatry Rep 21:118","journal-title":"Curr Psychiatry Rep"},{"key":"1640_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12874-017-0385-6","volume":"17","author":"DT Tran","year":"2017","unstructured":"Tran DT, Havard A, Jorm LR (2017) Data cleaning and management protocols for linked perinatal research data: a good practice example from the smoking MUMS (Maternal use of medications and Safety) study. BMC Med Res Methodol 17:97","journal-title":"BMC Med Res Methodol"},{"key":"1640_CR45","unstructured":"Tran D, Varney B, Jones N, Bharat C, Brett J, Oei J, Pearson S, Degenhardt L, Havard A (2025) Trends in opioid agonist treatment for opioid dependence during pregnancy: a population-based study in New South Wales 2005\u20132021. The Australasian Epidemiological Association Conference. Hobart, Tasmania, Australia"},{"key":"1640_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/1912526","volume":"50","author":"H White","year":"1982","unstructured":"White H (1982) Maximum likelihood estimation of misspecified models. Econometrica 50:1\u201325","journal-title":"Econometrica"},{"key":"1640_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.drugalcdep.2015.02.012","volume":"149","author":"C Wilder","year":"2015","unstructured":"Wilder C, Lewis D, Winhusen T (2015) Medication assisted treatment discontinuation in pregnant and postpartum women with opioid use disorder. Drug Alcohol Depend 149:225\u2013231","journal-title":"Drug Alcohol Depend"},{"key":"1640_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/birt.12569","volume":"49","author":"AN Wilson","year":"2022","unstructured":"Wilson AN, Sweet L, Vasilevski V, Hauck Y, Wynter K, Kuliukas L, Szabo RA, Homer CSE, Bradfield Z (2022) Australian women\u2019s experiences of receiving maternity care during the COVID-19 pandemic: a cross-sectional National survey. Birth 49:30\u201339","journal-title":"Birth"},{"key":"1640_CR49","unstructured":"World Health Organization (2014) Guidelines for the identification and management of substance use and substance use disorders in pregnancy [Online]. Available: https:\/\/www.who.int\/publications\/i\/item\/9789241548731 [Accessed: 13\/08\/2025]"},{"key":"1640_CR50","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/add.13462","volume":"111","author":"BK Zedler","year":"2016","unstructured":"Zedler BK, Mann AL, Kim MM, Amick HR, Joyce AR, Murrelle EL, Jones HE (2016) Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 111:2115\u20132128","journal-title":"Addiction"}],"container-title":["Archives of Women's Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00737-025-01640-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00737-025-01640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:24:42Z","timestamp":1772000682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00737-025-01640-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s00737-025-01640-8","relation":{},"ISSN":["1434-1816","1435-1102"],"issn-type":[{"value":"1434-1816","type":"print"},{"value":"1435-1102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the NSW Population & Health Services Research Ethics Committee (2018\/HRE0205; HREC\/18\/CIPHS5), the Aboriginal Health and Medical Research Council Research Ethics Committee (1400\/18), and Australian Institute of Health and Welfare Ethics Committee (EO2020\/3\/1173).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical consideration"}},{"value":"Due to the retrospective collection of existing data, informed consent was waived by the above-mentioned research ethics committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"6"}}